PNC Financial Services Group
XBIT icon

PNC Financial Services Group’s XBiotech XBIT Stock Holding History

PNC Financial Services Group’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,000
Closed -$65K – 4637
2021
Q3 		$65K Buy
+5,000
New +$79.7K ﹤0.01% 2917

Other funds holding XBIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PNC Financial Services Group's XBIT Position: Q4 2021 in Review

PNC Financial Services Group sold out of XBiotech (XBIT) in Q4 2021, closing a stake of 5,000 shares — an estimated $65K sold.

PNC Financial Services Group first reported a position in XBIT in Q3 2021 and held it in 1 quarter. The position peaked at $65K in Q3 2021. 61 funds tracked by Wall St. Rank hold XBIT as of Q4 2021.

  • PNC Financial Services Group reported no remaining XBiotech position as of Q4 2021 after selling out during the quarter.
  • PNC Financial Services Group sold 5,000 XBiotech shares in Q4 2021, an estimated $65K.
  • PNC Financial Services Group first reported a position in XBiotech in Q3 2021 and held it in 1 quarter.
  • PNC Financial Services Group's XBiotech position peaked at $65K in Q3 2021.
  • 61 funds tracked by Wall St. Rank held XBiotech as of Q4 2021.

Based on PNC Financial Services Group's 13F filing for Q4 2021, filed 11 Feb 2022.